The American Medical Association recently released its comments on the DEA’s proposed rules for controlled substance prescribing via telemedicine. Many telehealth providers are supportive of the organization's recommendations, such as its suggestion to extend the timeframe patients have to refill their buprenorphine prescription after their initial supply is prescribed via telemedicine.
The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance. The DEA touts the change as a way to ensure patient safety, but several telehealth advocates argue it will greatly disrupt access for those who need the drugs — especially at a time when the mental health and substance use crisis is growing.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
As healthcare organizations comply with the federal EPCS mandate, artificial intelligence and digital identity technologies should be utilized to detect, reduce, and remediate drug diversion.
Electronic prescribing of controlled substances (EPCS) is finally gaining momentum, but there are common misconceptions.